Idifarma launches accelerated pathway for complex drugs

14 July 2021

Spain-based contract development and manufacturing organization (CDMO) Idifarma has launched a new service to deliver an accelerated, effective path to clinic for innovative molecules.

“Simply to Clinic” uses Idifarma's expertise in oral standard and highly potent drugs to take projects from pre-formulation development through to clinical trial implementation, offering tailored services to develop, scale and manufacture product all under one roof at the facility in Pamplona, Spain.

The new service also aims to maximize yield and minimize waste of API and guarantees a quick, reliable, on time and in full delivery of batches for clinical trial, ensuring quality requirements that follow current GMP regulations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK